Loading...
Loading...
Anacor Pharmaceuticals
ANAC today announced that it has signed a
research agreement with the Bill & Melinda Gates Foundation (the Gates
Foundation) to discover drug candidates intended to treat two filarial worm
diseases (onchocerciasis, or river blindness, and lymphatic filariasis,
commonly known as elephantiasis) and tuberculosis (TB). Additionally, Anacor
will create an expanded library of boron compounds to screen for additional
potential drug candidates to treat neglected diseases and will provide access
to the expanded library compounds for neglected disease research to the Gates
Foundation, and others, including academic, governmental and other non-profit
institutions or equivalent entities. Under the agreement, Gates Foundation
will pay Anacor $17.7 million as well as invest $5 million in Anacor common
stock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in